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Clinical Infectious Diseases
M A J O R A R T I C L E
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Background. We report on the hepatitis C virus (HCV) epidemic among human immunodeﬁciency virus (HIV)-positive men
who have sex with men (MSM) in the United Kingdom and model its trajectory with or without scaled-up HCV direct-acting
antivirals (DAAs).
Methods. A dynamic HCV transmission model among HIV–diagnosed MSM in the United Kingdom was calibrated to HCV
prevalence (antibody [Ab] or RNA positive), incidence, and treatment from 2004 to 2011 among HIV-diagnosed MSM in the UK
Collaborative HIV Cohort (UK CHIC). The epidemic was projected with current or scaled-up HCV treatment, with or without a
20% behavioral risk reduction.
Results. HCV prevalence among HIV-positive MSM in UK CHIC increased from 7.3% in 2004 to 9.9% in 2011, whereas
primary incidence was ﬂat (1.02–1.38 per 100 person-years). Over the next decade, modeling suggests 94% of infections are at-
tributable to high-risk individuals, comprising 7% of the population. Without treatment, HCV chronic prevalence could have
been 38% higher in 2015 (11.9% vs 8.6%). With current treatment and sustained virological response rates (status quo), chronic
prevalence is likely to increase to 11% by 2025, but stabilize with DAA introduction in 2015. With DAA scale-up to 80% within 1
year of diagnosis (regardless of disease stage), and 20% per year thereafter, chronic prevalence could decline by 71% (to 3.2%)
compared to status quo in 2025. With additional behavioral interventions, chronic prevalence could decline further to <2.5%
by 2025.
Conclusions. Epidemiological data and modeling suggest a continuing HCV epidemic among HIV-diagnosed MSM in the
United Kingdom driven by high-risk individuals, despite high treatment rates. Substantial reductions in HCV transmission could
be achieved through scale-up of DAAs and moderately effective behavioral interventions.
Keywords. hepatitis C virus; HIV; men who have sex with men; antiviral treatment; prevention.
An epidemic of hepatitis C virus (HCV) among human immu-
nodeﬁciency virus (HIV)–positive men who have sex with men
(MSM) [1, 2] has been documented in cities in Europe, Austra-
lia, and the United States, but with little evidence of transmis-
sion among HIV-uninfected MSM [3, 4].One of the key hubs of
this epidemic is London [2].However, the state and future of the
UK epidemic is uncertain, with reported incidence based on
case notiﬁcations instead of longitudinal cohort trends [5, 6].
Modeling indicates that HCV antiviral treatment for those
at risk of transmission such as people who inject drugs
could have a primary prevention beneﬁt [7–10]. HIV-positive
MSM may be the ideal population to assess HCV treatment as
prevention (particularly with interferon [IFN]–free direct-
acting antiviral therapies [DAAs], which are highly effective
in this population [11, 12]), because most patients are linked
to care and frequently HCV tested, and the absolute numbers
of HCV/HIV-coinfected MSM are small. However, high rein-
fection rates (8–15/100 person-years [PY] [13–15]) among
HIV-positive MSM might limit the prevention beneﬁts of
HCV treatment.
To explore the potential impact of new treatments and other
interventions on this epidemic, we took advantage of detailed
available UK data and developed a dynamic model of HCV
transmission among HIV-positive MSM in the United King-
dom, to assess the epidemic trajectory and project the impact
of scaled-up HCV treatment as prevention.
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METHODS
Epidemiological Data Analysis
The UK Collaborative HIV Cohort (UK CHIC) study is an on-
going observational study collecting clinical data from 16 HIV
treatment centers across the United Kingdom [16]. Between
September 2012 and September 2013, additional data were col-
lected on HCV treatment from 11 participating centers. Indi-
viduals were included in the analysis if they had ever attended
one of the 11 centers since 2004, had an HCV antibody (anti-
HCV) or RNA test during follow-up, and were recorded as hav-
ing acquired HIV through sex between men.
Cumulative HCV prevalence was calculated yearly as the
number of men who had ever had a positive anti-HCV or
HCV RNA test by the end of that year as a proportion of all
those who had been tested by that time. Incident infection
was assessed among individuals with a negative anti-HCV test
and either negative or missing HCV RNA test after 1 January
2004 and at least 1 further test for anti-HCV or HCV RNA.
Individuals were followed up until a positive anti-HCV or
HCV RNA test or their last date seen at a UK CHIC center.
The incidence rate was calculated by dividing the total number
of incident infections (any positive anti-HCV or HCV RNA
test) by the total number of PY of follow-up. Receipt of
HCV treatment (IFN [pegylated or nonpegylated] with or
without ribavirin [RBV], telaprevir, or boceprevir) was as-
sessed among all men who had ever received a positive HCV
RNA result.
Mathematical Model
We developed a dynamic, deterministic model of HCV trans-
mission, progression, and treatment among diagnosed HIV-
positive MSM (Figure 1). Individuals enter at HIV diagnosis,
a small proportion with existing HCV coinfection. As the
model is dynamic, an individual’s risk of acquiring HCV is re-
lated to background HCV prevalence and his or her risk behav-
ior. The model tracks HCV disease progression and is stratiﬁed
by HCV diagnosis status, treatment history, and transmission
risk (high/low, based on factors associated with high risk of
HCV acquisition among MSM such as injecting drug use and
methamphetamine use [17, 18]). We assume MSM who inject
do so with other MSM, based on phylogenetic evidence indicat-
ing that HCV MSM strains are clustered separately from people
who inject drugs [19]. For our baseline analysis, we assume that
HCV-uninfected, HIV-diagnosed MSM are only at risk of HCV
acquisition from HIV-diagnosed MSM because of the low HCV
prevalence among HIV-uninfected MSM and HIV-positive un-
diagnosed MSM, proportional mixing between risk groups, and
movement between high/low risk.
Model Parameterization and Calibration
The model was calibrated to annual UK CHIC data on HCV
incidence, prevalence (Ab or RNA positive) and proportion
ever treated among diagnosed HIV-positive MSM in the United
Kingdom from 2004 to 2011, and parameterized by data among
HIV-diagnosed MSM in the United Kingdom (see list of param-
eters in Supplementary Table 1). The model was also calibrated
to estimate HCV reinfection incidence among HIV-positive
MSM in London (7.8/100 PY [95% conﬁdence interval {CI},
5.8–10.5/100 PY] across 2004–2012) [14] and the size of the
HIV-diagnosedMSM population in 2013 [20].Model projections
were validated against annual size estimates of the HIV-
diagnosed MSM population from 2001 to 2013 [20, 21].
Figure 1. Mathematical model schematic. The model is also stratified by treatment-naive, interferon-experienced, direct-acting antiviral–experienced, and low-/
high-risk states. Human immunodeficiency virus (HIV) and non-HIV death occurs from all states. Abbreviations: Ab, antibody; HCV, hepatitis C virus; MSM, men
who have sex with men.
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Based on UK CHIC data, we model treatment rates (from
2003 onward) of 46% (95% CI, 40%–53%) and 22% (95% CI,
20%–24%) treated within 1 year of an acute and chronic diagno-
sis, respectively. Using these rates and the cumulative proportion
ever treated by 2011 (44%), the model estimates an annual treat-
ment rate after the ﬁrst year of diagnosis of 6.8% (95% CI, 3.8%–
9.9%). Sustained virological response (SVR) rates for IFN-based
therapy among HIV-positive individuals came from a published
meta-analysis [22]; we assume 90% SVR with DAAs. We in-
creased life expectancy from HIV diagnosis over calendar time
based on UK data reﬂecting earlier diagnosis/treatment and
more effective antiretroviral therapy [23], and include excess
liver-related mortality for MSM coinfected with HCV [24, 25].
To incorporate parameter uncertainty, 1000 parameter sets
were randomly sampled from the parameter distributions
shown in Supplementary Table 1.
Intervention Scenarios and Sensitivity Analyses
We model the UK epidemic from 1996 to 2015, assessing the
population-attributable fraction of being high risk by assessing
the relative difference in cumulative new infections from 2015
to 2025 if the relative risk between high and low risk is set to
1 from 2015 and assuming status quo treatment rates and
SVR. We explore the 10-year impact (to 2025) on HCV (Ab or
RNA positive) prevalence, chronic (RNA positive) prevalence,
primary incidence, and numbers treated for the following
scenarios:
• Baseline status quo with IFN/RBV: continuation of current
treatment rates and SVR;
• Current treatment rates with DAAs for all: continuation of
current treatment rates with DAAs (90% SVR) from 2015;
• DAA scale-up at diagnosis: scale-up DAA treatment rates
to 60%/80%/100% treated within 1 year of diagnosis from 2015;
• DAA scale-up to all: scale up DAA treatment rates to 80%
treated within 1 year of diagnosis, and 20% per year thereafter
from 2015;
• DAA scale-up to all and behavioral intervention: as above
and 20% behavioral risk reduction from 2015; and
• No historical treatment from 1996.
We allow retreatment with DAAs for those who have previ-
ously failed IFN-based therapies and those who are reinfected.
One-way sensitivity analyses explore the impact of variations
in SVR, retreatment eligibility, HCV testing rates, risk reduc-
tions posttreatment (50% and 100%) or postdiagnosis (20%
for 1 year or until HCV treatment), assortative mixing, and
seeding of HCV from outside the HIV-diagnosed population
on the mean chronic HCV prevalence in 2025 for the DAA
scale-up to all scenario (Supplementary Data).
RESULTS
Epidemiological Data From UK CHIC
Nearly all (98%) of the MSM in UK CHIC under follow-up in
2011 had been tested for HCV (Table 1); the proportion of
MSM not known to be infected who were annually HCV tested
increased from 31% in 2004 to 65% in 2011 (Supplementary
Table 2). The median number of diagnostic tests until the
ﬁrst positive result per individual was 4 (interquartile range,
2–6).
The cumulative HCV prevalence (Ab or RNA positive)
among HIV-positive MSM increased from 7.26% in 2004 to
9.86% in 2011 (Table 1). A total of 11 386 MSM, who were ini-
tially HCV uninfected and who had at least 1 further test during
a median of 5 years’ follow-up, were included in the incidence
analysis, contributing 54 619 PY of follow-up. Incidence rates
from 2004 to 2011 were relatively ﬂat, varying from 1.02 to
1.38/100 PY of follow-up (Table 2).
A total of 1403 MSM had ever received a positive RNA result
and were considered eligible for HCV treatment. Of these, 36
individuals were excluded as their treatment dates were prior
to their ﬁrst positive HCV tests. Therefore, a total of 1367
MSM were eligible for inclusion in this analysis. Overall, 586
Table 1. Cumulative Prevalence (Antibody or RNA Positive) of Hepatitis C Among Human Immunodeficiency Virus (HIV)-Positive Men Who Have Sex With
Men in the UK Collaborative HIV Cohort Study
Year
Total No. of MSM Under
Follow-up in That Year in
UK CHIC
Total No. of MSM Under Follow-up
in That Year With a Reported Test
by End of Year
% With an HCV Test
Reported by End of That
Year
Cumulative No.
HCV Infected (Ab
or RNA Positive)
Cumulative HCV
Prevalence (Ab or RNA
Positive), %
2004 11 012 6774 61.51 492 7.26
2005 11 765 8398 71.38 641 7.63
2006 12 335 9550 77.42 752 7.87
2007 12 895 10 808 83.82 896 8.29
2008 13 262 11 799 88.97 1049 8.89
2009 13 693 12 607 92.07 1195 9.48
2010 14 147 13 369 94.50 1293 9.67
2011 13 101 12 789 97.62 1261 9.86
Ever 17 574 16 533 94.08 1673 10.12
Abbreviations: Ab, antibody; HCV, hepatitis C virus; MSM, men who have sex with men; UK CHIC, Collaborative HIV Cohort.
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of 1367 (43%) were ever treated, the majority (60%) of treat-
ments occurring within 1 year of diagnosis (Supplementary Ta-
bles 3 and 4).
Modeling Projections
The model ﬁts closely matched the number of HIV-diagnosed
MSM from 2000 to 2013 (Figure 2A) and HCV prevalence (Ab
or RNA positive) from 2004 to 2011 (Figure 2B). The projected
HCV incidence (1.47/100 PY) was toward the upper bounds of
the UK CHIC data (Figure 2C), and projected reinfection inci-
dence (mean, 7.8/100 PY for 2004–2012) was consistent with
UK data [14]. In 2015, the modeled reinfection incidence
ranged from 4- to 7-fold that of the primary incidence.
Population-Attributable Fractions
The model ﬁts estimate a high-risk population size of 7%
(2.5%–97.5% interval [95% CI, 3%–14%]), consistent with the
estimated proportion of HIV-positive MSM in the United
Kingdom reporting injecting drug use or methamphetamine
use in the previous 4 weeks [26]. These high-risk individuals
contribute more than one-third of prevalent (37% [95% CI,
21%–64%]) and incident (36% [95% CI, 13%–78%]) infections
in 2015. Over the next decade, 94% (95% CI, 91%–97%) of in-
fections are attributable to high-risk individuals.
Projections of Intervention Impact to 2025
A summary of the modelled scenarios can be found in Table 3.
Treatment With IFN/RBV
If HCV treatment and SVR rates remain unchanged, the model
predicts steadily increasing anti-HCV prevalence, and increas-
ing chronic (RNA positive) prevalence from 8.6% (95% CI,
8.1%–9.1%) in 2015 to 11% (95% CI, 9.9%–12.1%) in 2025 (Fig-
ure 3A and 3B). Due to the expanding epidemic, status quo
treatment rates result in greater treatments required yearly
(Figure 4). In contrast, incidence will remain relatively ﬂat, at
1.5/100 PY (95% CI, 1.4–1.7/100 PY) in 2025 (Figure 3C).
However, if there was no treatment, chronic prevalence would
have been more than one-third (38%) higher in 2015 (11.9%
[95% CI, 11.1%–12.6%]), and 17.4% (95% CI, 15.8%–18.6%)
in 2025 (Figure 3B). Similarly, incidence would have been
24% higher (1.8/100 PY [95% CI, 1.6–2/100 PY]).
Treatment With DAAs
If DAAs are provided from 2015 at current treatment rates, chron-
ic prevalence will remain virtually unchanged over the next dec-
ade (8% [95% CI, 7.4%–8.6%] in 2025), but could be a relative
27% lower in 2025 than if IFN/RBV is used (Figure 3B). Modest
Figure 2. Model fits to epidemiological data from the United Kingdom. A, Num-
ber of human immunodeficiency virus (HIV)-diagnosed men who have sex with men
(MSM). B, Hepatitis C virus (HCV) prevalence (antibody [Ab] or RNA positive) among
diagnosed HIV-diagnosed MSM. C, HCV primary incidence among diagnosed HIV-
diagnosed MSM. Solid lines show the mean value of all 1000 simulations; dashed
lines show the 2.5% and 97.5% range of the projections. Black diamonds show data
from Public Health England (A; model calibrated to 2013 value, other values shown
for validation) and UK Collaborative HIV Cohort (B and C; model calibrated against all
data points).
Table 2. Incidence of Hepatitis C Among Human Immunodeficiency Virus
(HIV)-Positive Men Who Have Sex With Men in the UK Collaborative HIV
Cohort Study
Year
PY of Follow-up of Those
HCV Ab Negative
New
Infections
Incidence/100 PY of
Follow-up (95% CI)
2004 1454 15 1.03 (.58–1.70)
2005 4179 51 1.22 (.91–1.60)
2006 6076 62 1.02 (.78–1.31)
2007 7484 103 1.38 (1.12–1.67)
2008 8752 106 1.21 (.99–1.46)
2009 9405 111 1.18 (.97–1.42)
2010 9782 101 1.03 (.84–1.25)
2011 7487 80 1.07 (.85–1.33)
Abbreviations: Ab, antibody; CI, confidence interval; HCV, hepatitis C virus; PY, person-years.
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Table 3. Mathematical Modeling Scenarios
Model Scenario
SVR <1 y From
HCV Infection
(Sampled Range)
SVR >1 y After
Acute Infection
(Sampled Range)
Proportion Treated
After Acute Diagnosis
(Sampled Range)
Proportion Treated the
First Year After Chronic
Diagnosis (Sampled
Range)
Proportion
Treated
Thereafter
Behavioral
Intervention
Baseline status quo with
IFN/RBV
80% (70%–90%) 30% (25%–35%) 46% (40%–53%) 22% (20%–24%) Mean 5.9%
(2.5%–97.5%
fits 3.5–10)
No
Current treatment with
DAA for all
90% 90% As in baseline As in baseline As in baseline No
DAA scale-up at diagnosis 90% 90% 60%/80%/100% 60%/80%/100% As in baseline No
DAA scale-up to all 90% 90% 80% 80% 20% No
DAA scale-up to all and
behavioral intervention
90% 90% 80% 80% 20% 20% reduction
in risk for all
No historical treatment NA NA 0% (no treatment
from 1996)
0% (no treatment from
1996)
0% (no
treatment from
1996)
No
Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; IFN/RBV, pegylated interferon + ribavirin; NA, not applicable; SVR, sustained virological response.
Figure 3. Model projections (mean value of 1000 simulations shown) with various treatment scenarios in the United Kingdom. A, Hepatitis C virus (HCV) prevalence
(antibody [Ab] or RNA positive) among human immunodeficiency virus (HIV)–diagnosed men who have sex with men (MSM). B, HCV chronic (RNA) prevalence among HIV-
diagnosed MSM. C, HCV primary incidence among HIV-diagnosed MSM. Abbreviations: DAA, direct-acting antiviral; IFN/RBV, interferon/ribavirin; py, person-years; SVR,
sustained virological response.
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reductions in HCV incidence would be achieved (1.3/100 PY
[95% CI, 1.2–1.4/100 PY] in 2025) (Figure 3C).
Treatment Scale-up With DAAs
Substantial reductions in chronic prevalence can be achieved
through scale-up of DAAs (Figure 3B). If 60%, 80%, or 100%
of recently diagnosed (<1 year) individuals are treated the
year of diagnosis (compared with 46% at baseline) but there
is no change in treatment rates for nonrecent diagnoses (>1
year), HCV RNA prevalence in 2025 could decrease to 7.4%
(95% CI, 6.7%–8.1%), 6.2% (95% CI, 5.6%–7%), or 5.0%
(95% CI, 4.4%–6%), respectively (a 33%, 44%, or 55% relative
reduction compared with baseline, respectively). Similarly, inci-
dence in 2025 could decline relatively by 15%, 25%, and 36%
compared with baseline, respectively. These treatment increases
result in 15%, 30%, and 41% greater numbers treated for the
ﬁrst year, respectively, but the annual numbers treated drop
below the status quo scenario by 2022 (Figure 4).
More impact is achieved if treatment is scaled up among those
with recent (<1 year) and nonrecent (>1 year) diagnoses. If 80%
of recent diagnoses and 20% per year of nonrecent diagnoses are
treated (compared with 46% and 7%, respectively, at baseline),
RNA prevalence could decline to 3.2% (95% CI, 2.8%–4.1%) by
2025 (71% lower than 2025 baseline), and incidence could decline
to 0.7/100 PY (95% CI, 0.6–1/100 PY) (56% lower than 2025
baseline). Treatment numbers double the ﬁrst year, but drop
quickly, approaching the status quo scenario by 2022 (Figure 4).
If DAA scale-up (80% <1 year from diagnosis and 20% per
year thereafter) is combined with a behavioral intervention that
reduces transmission risk by 20% from 2015, HCV incidence de-
creases by 20% within 1 year to 1.2/100 PY (95% CI, 1.1–1.3/100
PY), and to 0.4/100 PY (95% CI, 0.3–0.7/100 PY) by 2025 (Fig-
ure 3C). This combined prevention intervention reduces chronic
prevalence to 2.4% (95% CI, 2.1%–3.3%) by 2025 (Figure 3B) and
lowers the annual number of treatments (Figure 4).
Sensitivity Analysis
Across our sensitivity analyses, all scenarios predict a chronic RNA
prevalence of <4% in 2025 with DAA scale-up to all (compared to
3.2% for base case). Less impact (35% relative reduction in chronic
prevalence at 2025 compared to base case) is achieved with no re-
treatment because high treatment rates are not sustainable due to
many MSM already being treated. Although greater impact occurs
if risk reductions occur posttreatment from 2015 (20% greater im-
pact if risk is reduced by 100%), the effect is limited as retreatment
of reinfections is high. Little additional impact (<3% relative differ-
ence) is achieved with a short-term (<1 year) 20% reduction in risk
behavior after diagnosis; more substantial impact by 2025 occurs
with a sustained behavioral intervention targeting all MSM
(chronic RNA, 2.4% in 2025) than a short-term intervention
targeting those postdiagnosis (chronic RNA, 3.1% in 2025). Little
difference (<15% relative difference) is seen with varied SVR,
scaled-up diagnosis, partial assortative mixing of high risk, or if
HCV infections are seeded into the population (Supplementary
Figure 1).
DISCUSSION
HCV prevalence (Ab or RNA positive) among HIV-diagnosed
MSM in the UK CHIC study is projected to increase under cur-
rent treatment rates from 9.9% in 2011 to 11% by 2025. We es-
timate that a small high-risk group (<10%) contributes >90% of
HCV infections over the next decade. To substantially reduce
chronic prevalence (<3%), treatment scale-up among all diag-
nosed individuals is required, with behavior change interven-
tions necessary to achieve immediate reductions in HCV
incidence. The scaled-up rates we examine translate to a maxi-
mum of double the numbers of HIV-positive MSM treated
(700/year in the United Kingdom) compared to the status
quo initially, but these numbers drop below status quo levels
by 2022 due to prevention beneﬁts.
Figure 4. Model projections of the mean number of hepatitis C virus (HCV) treatments for human immunodeficiency virus (HIV)-diagnosed men who have sex with men
(MSM) in the United Kingdom for different treatment scenarios. Abbreviations: DAA, direct-acting antiviral; IFN/RBV, interferon/ribavirin; SVR, sustained virological response.
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To our knowledge, this is the ﬁrst study to model the HCV
epidemic among HIV-positive MSM. Although our analysis is
UK-focused, other settings have similar incidence [27–29]. The
stable incidence levels found in the United Kingdom are similar
to those in Amsterdam [29] and the United States [30], whereas
increasing incidence is reported in Switzerland [28]. Given its
large size and wide representation of UK clinics, UK CHIC is
broadly representative of people living with HIV and attending
for HIV care in the United Kingdom. Our UK CHIC estimate is
slightly higher than reported previously in the United Kingdom
[5, 6], based on case notiﬁcation data, but also slightly lower
than projected by our modeling. Two potential sources of under-
estimation by UK CHIC data could be due to incident infections
without a previous negative test being excluded, or follow-up time
being overestimated for patients who cycle in and out of UK
CHIC clinics, which, if occurring among higher-risk individuals,
could lead to true incidence being underestimated. On the other
hand, it is possible those tested are at higher risk of infection,
which would overestimate true incidence.
The model projections are limited by several sources of un-
certainty that remain even after the uncertainty analyses.
First, we model HCV transmission among HIV-diagnosed
MSM only, although we include inﬂow of HIV/HCV-coinfected
individuals at HIV diagnosis who are unaffected by our inter-
ventions. It is possible that interventions for HIV-diagnosed
MSM would also reduce incidence among HIV-undiagnosed
MSM, in which case we would expect more impact than shown.
Additionally, our sensitivity analysis suggests that seeding of
HCV infections from HIV-undiagnosed or HIV-uninfected in-
dividuals would have minimal impact. It is unclear whether the
higher HCV prevalence among HIV-diagnosed MSM com-
pared with that among HIV-undiagnosed or HIV-uninfected
individuals is related to changing risk behavior upon HIV diag-
nosis, a longer time at risk, or individuals with elevated risk be-
haviors compared with the general MSM population acquiring
both HIV and HCV.
Second, there are limited data deﬁning HCV-related risk be-
haviors among HIV-positive MSM, and therefore we allowed de-
tails of the high-risk population (size, relative risk, time at risk) to
vary as part of the model calibration. Additionally, although we
include behavioral heterogeneity, we do not explicitly model the
transmission network. It is possible that highly connected super-
spreaders are responsible for manyHCV transmission events and
should be targeted for prevention. Similarly, we neglect interna-
tional migration/travel due to a lack of available data, movement
that could seed infections and limit the impact of localized inter-
ventions. Better epidemiological data on these factors is critical to
strengthening the model predictions.
Third, we explore a hypothetical 20% effective behavioral risk
intervention, which was not based on a proven intervention in
this population. Unfortunately, there is no empirical evidence
that this level of HCV risk reduction is achievable. A Cochrane
review found evidence for the effectiveness of behavior change
interventions (eg, counseling, social and behavioral support) to
reduce unprotected anal sex among MSM, reporting an overall
reduction by 27% (95% CI, 15%–37%) [31]. These interventions,
though primarily aimed at reducing HIV risk, could be effective
for HCV as well. Additionally, among people who inject drugs,
opiate substitution therapy and high-coverage needle and syringe
programs can reduce an individual’s risk of HCV acquisition by
50% alone, or 80% in combination [32], but it is unclear how ap-
plicable these interventions are to the HCV epidemic among
MSM. It is possible that both sexual and injecting-related inter-
ventions could play an important role, such as prevention mes-
saging training among sexual health/HIV clinic staff and the
distribution of safe “chemsex” kits. One UK clinic is currently ex-
amining the impact of club drug behavior change intervention
among MSM, but the impact is uncertain at present.
Fourth, we examine DAA scale-up for both acute and chronic
infection, as European [33] and US [34] guidelines recommend
DAA therapy regardless of liver disease stage for HIV/HCV-
coinfected individuals. However, if DAAs are prioritized or
restricted to those with more advanced liver disease, then the
prevention impact could be less than we predict. As such, the
individual and population beneﬁts achievable strongly support
not restricting access to DAA therapy among HIV/HCV-
coinfected MSM. Nevertheless, even if IFN-free DAA therapy
is prioritized to those with advanced liver disease, it is possible
that IFN-based treatment uptake among those with less ad-
vanced disease will remain high given historically high rates
of uptake among HIV-coinfected MSM.
CONCLUSIONS
We report a continuing HCV epidemic among HIV-diagnosed
MSM in the United Kingdom, despite high rates of treatment,
which is largely attributable to a high-risk population. Substantial
reductions in HCV transmission within a decade could be
achieved through rapid DAA scale-up and moderately successful
behavioral interventions. This impact could be achieved despite
reinfection rates that are roughly 5-fold higher than primary inci-
dence, because the shortening and ease of delivery of new IFN-free
DAAs enables scale-up with existing infrastructure. Given their
importance in driving ongoing HCV transmission, there is a
need to develop effective interventions to address high-risk behav-
iors associated with injecting and other drug use among MSM.
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